Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Bipolar psychopharmacotherapy [[electronic resource] ] : caring for the patient / / edited by Hagop Akiskal and Mauricio Tohen
| Bipolar psychopharmacotherapy [[electronic resource] ] : caring for the patient / / edited by Hagop Akiskal and Mauricio Tohen |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex, : John Wiley & Sons, c2011 |
| Descrizione fisica | 1 online resource (546 p.) |
| Disciplina | 616.895 |
| Altri autori (Persone) |
AkiskalHagop S
TohenMauricio |
| Soggetto topico |
Bipolar disorder - Chemotherapy
Lithium - Therapeutic use Antipsychotic drugs Psychopharmacology |
| ISBN |
0-470-97698-5
1-119-95664-1 1-283-37293-2 9786613372932 0-470-97510-5 0-470-97511-3 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Bipolar Psychopharmacotherapy; Contents; List of Contributors; Preface to the Second Edition; Chapter 1 The scope of bipolar disorders; 1.1 Diagnostic and public health aspects; 1.2 Psychological and social aspects; Appendix 1.A: Laboratory considerations in the clinical use of lithium; References; Chapter 2 Lithium treatment: Focus on long-term prophylaxis; 2.1 Introduction; 2.2 Cade's pioneering study; 2.3 Discovery of the prophylactic action of lithium; 2.4 Practical issues; 2.5 Are new and better prophylactic agents about to oust lithium?; 2.6 Combination treatment
2.7 Prophylaxis in recurrent depressive disorder 2.8 The effect of lithium on the patients' suicidal behavior; 2.9 Benefits of prophylactic lithium treatment; 2.10 Conclusion; References; Chapter 3 Valproate: Clinical pharmacological profile; 3.1 Historical background; 3.2 Structure-activity relationships; 3.3 Pharmacodynamic properties; 3.4 Pharmacokinetics and metabolic clearance; 3.5 Serum concentration and efficacy; 3.6 Efficacy and indications; 3.7 Efficacy in bipolar disorder; 3.8 Combination strategy in acute mania; 3.9 Prophylaxis in bipolar disorder 3.10 Treatment of bipolar depression 3.11 Valproate in treatment of bipolar disorder in children and adolescents; 3.12 Use in bipolar illness comorbid with alcoholism; 3.13 Bipolar disorder comorbid with ADHD; 3.14 Bipolar disorder comorbid with borderline personality disorder; 3.15 Adverse effects; 3.16 Comparative adverse effects; 3.17 Adverse effects in combination therapy, compared with monotherapy; 3.18 Adverse effects by bodily system; 3.19 Summary; References; Chapter 4 Pharmacological profile and clinical utility of lamotrigine in mood disorders; 4.1 Introduction 4.2 Clinical pharmacology of lamotrigine 4.3 Lamotrigine and mood disorders; 4.4 Safety; 4.5 Clinical applications for lamotrigine in mood disorders; 4.6 Summary; References; Chapter 5 Carbamazepine and other anticonvulsants; 5.1 Introduction; 5.2 Conclusions; References; Chapter 6 Olanzapine in treatment for bipolar disorder; 6.1 Introduction; 6.2 Rationale in the clinical trial development of olanzapine; 6.3 Efficacy in the treatment of acute mania; 6.4 Efficacy in the treatment of bipolar depression; 6.5 Efficacy in bipolar maintenance/relapse prevention; 6.6 Safety and tolerability 6.7 Summary References; Chapter 7 Haloperidol and other first generation antipsychotics in mania; 7.1 Introduction; 7.2 Acute tranquillization in mania; 7.3 Sedation is not required for antipsychotics to improve mania; 7.4 Chlorpromazine in mania; 7.5 Haloperidol in mania; 7.6 Hormone changes and mechanisms of antimanic effects of antipsychotics; 7.7 Antipsychotics as mood stabilizers; 7.8 Placebo-controlled studies in mania; 7.9 Recent comparative trials without placebo; 7.10 Pharmacoeconomics; 7.11 Conclusions; Declaration of interest; References Chapter 8 Clinical utility of clozapine in bipolar disorder |
| Record Nr. | UNINA-9910131046403321 |
| Chichester, West Sussex, : John Wiley & Sons, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Bipolar psychopharmacotherapy : caring for the patient / / edited by Hagop Akiskal and Mauricio Tohen
| Bipolar psychopharmacotherapy : caring for the patient / / edited by Hagop Akiskal and Mauricio Tohen |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex, : John Wiley & Sons, c2011 |
| Descrizione fisica | 1 online resource (546 p.) |
| Disciplina | 616.895 |
| Altri autori (Persone) |
AkiskalHagop S
TohenMauricio |
| Soggetto topico |
Bipolar disorder - Chemotherapy
Lithium - Therapeutic use Antipsychotic drugs Psychopharmacology |
| ISBN |
0-470-97698-5
1-119-95664-1 1-283-37293-2 9786613372932 0-470-97510-5 0-470-97511-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Bipolar Psychopharmacotherapy; Contents; List of Contributors; Preface to the Second Edition; Chapter 1 The scope of bipolar disorders; 1.1 Diagnostic and public health aspects; 1.2 Psychological and social aspects; Appendix 1.A: Laboratory considerations in the clinical use of lithium; References; Chapter 2 Lithium treatment: Focus on long-term prophylaxis; 2.1 Introduction; 2.2 Cade's pioneering study; 2.3 Discovery of the prophylactic action of lithium; 2.4 Practical issues; 2.5 Are new and better prophylactic agents about to oust lithium?; 2.6 Combination treatment
2.7 Prophylaxis in recurrent depressive disorder 2.8 The effect of lithium on the patients' suicidal behavior; 2.9 Benefits of prophylactic lithium treatment; 2.10 Conclusion; References; Chapter 3 Valproate: Clinical pharmacological profile; 3.1 Historical background; 3.2 Structure-activity relationships; 3.3 Pharmacodynamic properties; 3.4 Pharmacokinetics and metabolic clearance; 3.5 Serum concentration and efficacy; 3.6 Efficacy and indications; 3.7 Efficacy in bipolar disorder; 3.8 Combination strategy in acute mania; 3.9 Prophylaxis in bipolar disorder 3.10 Treatment of bipolar depression 3.11 Valproate in treatment of bipolar disorder in children and adolescents; 3.12 Use in bipolar illness comorbid with alcoholism; 3.13 Bipolar disorder comorbid with ADHD; 3.14 Bipolar disorder comorbid with borderline personality disorder; 3.15 Adverse effects; 3.16 Comparative adverse effects; 3.17 Adverse effects in combination therapy, compared with monotherapy; 3.18 Adverse effects by bodily system; 3.19 Summary; References; Chapter 4 Pharmacological profile and clinical utility of lamotrigine in mood disorders; 4.1 Introduction 4.2 Clinical pharmacology of lamotrigine 4.3 Lamotrigine and mood disorders; 4.4 Safety; 4.5 Clinical applications for lamotrigine in mood disorders; 4.6 Summary; References; Chapter 5 Carbamazepine and other anticonvulsants; 5.1 Introduction; 5.2 Conclusions; References; Chapter 6 Olanzapine in treatment for bipolar disorder; 6.1 Introduction; 6.2 Rationale in the clinical trial development of olanzapine; 6.3 Efficacy in the treatment of acute mania; 6.4 Efficacy in the treatment of bipolar depression; 6.5 Efficacy in bipolar maintenance/relapse prevention; 6.6 Safety and tolerability 6.7 Summary References; Chapter 7 Haloperidol and other first generation antipsychotics in mania; 7.1 Introduction; 7.2 Acute tranquillization in mania; 7.3 Sedation is not required for antipsychotics to improve mania; 7.4 Chlorpromazine in mania; 7.5 Haloperidol in mania; 7.6 Hormone changes and mechanisms of antimanic effects of antipsychotics; 7.7 Antipsychotics as mood stabilizers; 7.8 Placebo-controlled studies in mania; 7.9 Recent comparative trials without placebo; 7.10 Pharmacoeconomics; 7.11 Conclusions; Declaration of interest; References Chapter 8 Clinical utility of clozapine in bipolar disorder |
| Record Nr. | UNINA-9910813763403321 |
| Chichester, West Sussex, : John Wiley & Sons, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
